Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs CRSP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FDMT Captures Overall Composite Edge (42.1 HOLD vs 48.6 HOLD), While CRSP Leads 3–2 on Growth & Valuation Pillars
FDMT Overall Winner
6-Pillar Tally: FDMT 2 – 3 CRSP (1 Tie)
Matrix Metrics: FDMT 3 – 7 CRSP
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over CRISPR Therapeutics AG (CRSP) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 3–7 (led by Growth & Scale, Balance Sheet & Cash Flow), while CRSP wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CRSP at $40.61 (23.4x Forward P/E, -2058.6% operating margin).
- Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -2058.6% operating margin) and revenue trajectory (+4505.6% vs. +1325.1% YoY).
- Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FDMT vs CRSP
FDMT
Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
$11.65
-4.74% 1D
Market Cap
$669.3M
TTM Revenue
$96M
Forward P/E
N/M
Beta / 30D Vol
1.89β · 90% Vol
Unified Composite Score
42.1
HOLD
Tech 21.0
Fund 54.0
Flow 66.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
CRSP
CRISPR Therapeutics AG
$40.61
-3.86% 1D
Market Cap
$4.1B
TTM Revenue
$25M
Forward P/E
23.4x
Beta / 30D Vol
1.85β · 60% Vol
Unified Composite Score
48.6
HOLD
Tech 33.0
Fund 51.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (FDMT 2 – 3 CRSP)
1. Valuation Multiples
CRSP
Forward P/E
N/M
23.4x
Trailing P/E
N/M
23.4x
PEG Ratio
N/M
N/M
EV / Revenue
6.6x
N/M
2. Growth & Scale
FDMT
Revenue Growth (YoY)
+4505.6%
+1325.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$96M
$25M
Market Cap
$669.3M
$4.1B
3. Profitability & Quality
CRSP
Gross Margin
N/A
N/A
Operating Margin
-222.7%
-2058.6%
Net Profit Margin
-208.6%
0.0%
Return on Equity (ROE)
-56.7%
-25.6%
4. Balance Sheet & Cash Flow
FDMT
Cash Generation (TTM)
-$156M
-$378M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$31M Net Cash
$588M Net Debt (0.47x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CRSP
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
82.4% (10th %ile)
97.8% (52nd %ile)
Put/Call OI Skew
5.16x (Put-Skewed)
0.65x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FDMT (3) vs CRSP (7)| Institutional Metric | FDMT | CRSP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $669.3M | $4.1B | CRSP | |
| Trailing P/E Ratio | N/M | 23.4x | CRSP | |
| Forward P/E Ratio | N/M | 23.4x | CRSP | |
| Revenue Growth (YoY) | +4505.6% | +1325.1% | FDMT | |
| Operating Margin (TTM) | -222.7% | -2058.6% | FDMT | |
| Net Profit Margin | -208.6% | 0.0% | CRSP | |
| Return on Equity (ROE) | -56.7% | -25.6% | CRSP | |
| 52-Week Range Position | 47% ($7–$17) | 1% ($40–$63) | FDMT | |
| Beta / 30D Volatility | 1.89β · 90% Vol | 1.85β · 60% Vol | CRSP | |
| Unified Institutional Score | 42.1 / 100 (HOLD) | 48.6 / 100 (HOLD) | CRSP | |
| Trailing 12M Revenue (USD) | $96M | $25M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$156M ($31M Net Cash) | -$378M ($588M Net Debt (0.47x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
FDMT +13.5 pp
3M Horizon
FDMT +2.47 pp
6M Horizon
FDMT +55.64 pp
1Y Horizon
FDMT +33.87 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | CRSP Revenue | FDMT Op. Margin | CRSP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -5087.8% | CRSP |
| FY2019 | $10M | $290M | -729.4% | 16.1% | CRSP |
| FY2020 | $10M | $0M | -424.0% | -49295.5% | FDMT |
| FY2021 | $20M | $910M | -395.5% | 40.8% | CRSP |
| FY2022 | $0M | $0M | -3516.5% | -56190.4% | FDMT |
| FY2023 | $20M | $370M | -544.6% | -60.0% | CRSP |
| FY2024 | $0M | $40M | -507678.4% | -1250.4% | CRSP |
| FY2025 | $90M | $0M | -187.2% | -18933.6% | FDMT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FDMT
BREAKDOWN
Current IV
82.4%
IV Percentile
10th %ile
Put/Call OI Skew
5.16x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CRSP
BREAKDOWN
Current IV
97.8%
IV Percentile
52nd %ile
Put/Call OI Skew
0.65x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FDMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CRSP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FDMT vs CRSP Key Questions & Quantitative Answers
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over CRISPR Therapeutics AG (CRSP) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 3–7 (led by Growth & Scale, Balance Sheet & Cash Flow), while CRSP wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CRSP at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -2058.6% operating margin) and revenue trajectory (+4505.6% vs. +1325.1% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FDMT cumulative revenue shifted +800.0% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.
CRSP screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus CRSP (-25.6% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CRSP vs FDMT · Reverse Pair
FDMT vs STOK
· Sector Peer
FDMT vs ANNX
· Sector Peer
FDMT vs CGEM
· Sector Peer
CRSP vs NTLA
· Sector Peer
CRSP vs TDOC
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem